advertisement
Abstract #13299 Published in IGR 8-1
Development of specific Rho-kinase inhibitors and their clinical application
Tamura M; Nakao H; Yoshizaki H; Shiratsuchi M; Shigyo H; Yamada H; Ozawa T; Totsuka J; Hidaka HBiochimica et Biophysica Acta Proteins and Proteomics 2005; 1754: 245-252
Hexahydro-1-(isoquinoline-5-sulfonyl)-1H-1,4-diazepine, HA-1077, is a known selective inhibitor of Rho-kinase. Although its IC50 value against Rho-kinase is more than 10 times lower than those for kinases such as PKA, PKB, PKC, PKG, MLCK, CaMKII and others, the molecule still retains relative potent inhibition activities against these kinases. In order to produce highly specific Rho-kinase inhibitors, several HA-1077 analogs were synthesized and their kinase inhibition properties evaluated. (S)-Hexahydro-1-(4-ethenylisoquinoline- 5-sulfonyl)-2-methyl-1H-1,4-diazepine was found to be a potent Rho-kinase inhibitor. The IC50 value against Rho-kinase was 6 nM, while those against other kinases remained at almost the same level as that of HA-1077. Furthermore, we designed HA-1077 analogs on the basis of the complex structure of PKA and HA-1077. Amongst these, (S)-hexahydro-4-glycyl-2-methyl-1-(4- methylisoquinoline-5-sulfonyl)-1H-1,4-diazepine and other glycine derivatives were found to be highly specific Rho-kinase inhibitors. These Rho-kinase specific inhibitors were applied to rabbit ocular hypertensive models and were shown to reduce intraocular pressure. These results demonstrate that the new 5-isoquinolinesulfonylamides are not only potent ROCK selective compounds, but are also useful compounds for clinical applications.
Dr. H. Hidaka, D. Western Therapeutics Institute, Yagoto Building, 100-32 Yagotohonmachi, Showa-ku, Nagoya 466-0825, Japan
Classification:
11.14 Investigational drugs; pharmacological experiments (Part of: 11 Medical treatment)
